Care.diabetesjournals.org

Why is heart failure not more rigorously assessed in clinical trials of antidiabetes drugs? In a Personal View, published in The Lancet Diabetes & Endocrinology journal, Professor John McMurray of The University of Glasgow and colleagues...

(Reuters Health) – Six-and-a-half years of intensive diabetes control may protect against heart attack and stroke for the next 30 years, according to long-term results from a U.S. trial that began in the 1980s. Participants in the Diabetes Control and...

Results from a trial study, have proven to reduce cardiovascular risks in vulnerable patients with Type 2 diabetes. Liraglutide, the drug under evaluation in the trial, is one of top diabetes two injectable medicines currently in the market, to treat...

American Diabetes Association President, Medicine & Science, makes fiery plea to create a sense of urgency about diabetes. Photo by © ADA/Susan Poag. If you were looking for the world’s leading diabetes researchers last week, you would have found...

THE WOODLANDS, Texas, June 6, 2015 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the manuscript entitled "Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes" was presented today...